Pfizer Operating Expenses 2010-2022 | PFE

Pfizer annual/quarterly operating expenses history and growth rate from 2010 to 2022. Operating expenses can be defined as the sum of all operating expenses for the given industry.
  • Pfizer operating expenses for the quarter ending June 30, 2022 were $15.523B, a 16.14% increase year-over-year.
  • Pfizer operating expenses for the twelve months ending June 30, 2022 were $70.445B, a 68.75% increase year-over-year.
  • Pfizer annual operating expenses for 2021 were $61.855B, a 85.19% increase from 2020.
  • Pfizer annual operating expenses for 2020 were $33.401B, a 2.32% decline from 2019.
  • Pfizer annual operating expenses for 2019 were $34.195B, a 2.73% decline from 2018.
Pfizer Annual Operating Expenses
(Millions of US $)
2021 $61,855
2020 $33,401
2019 $34,195
2018 $35,153
2017 $38,824
2016 $40,679
2015 $37,027
2014 $36,356
2013 $36,400
2012 $39,393
2011 $47,068
2010 $51,753
2009 $38,310
Pfizer Quarterly Operating Expenses
(Millions of US $)
2022-06-30 $15,523
2022-03-31 $16,260
2021-12-31 $20,710
2021-09-30 $17,952
2021-06-30 $13,366
2021-03-31 $9,827
2020-12-31 $10,724
2020-09-30 $7,829
2020-06-30 $7,792
2020-03-31 $7,056
2019-12-31 $6,771
2019-09-30 $9,722
2019-06-30 $8,998
2019-03-31 $8,704
2018-12-31 $7,172
2018-09-30 $9,534
2018-06-30 $9,490
2018-03-31 $8,957
2017-12-31 $11,396
2017-09-30 $9,504
2017-06-30 $9,155
2017-03-31 $8,769
2016-12-31 $11,871
2016-09-30 $10,024
2016-06-30 $9,670
2016-03-31 $9,114
2015-12-31 $12,213
2015-09-30 $8,729
2015-06-30 $8,258
2015-03-31 $7,827
2014-12-31 $10,971
2014-09-30 $8,679
2014-06-30 $8,823
2014-03-31 $7,883
2013-12-31 $10,515
2013-09-30 $8,659
2013-06-30 $8,686
2013-03-31 $8,540
2012-12-31 $10,291
2012-09-30 $9,210
2012-06-30 $9,100
2012-03-31 $10,792
2011-12-31 $9,526
2011-09-30 $12,521
2011-06-30 $12,464
2011-03-31 $12,557
2010-12-31 $13,575
2010-09-30 $12,232
2010-06-30 $12,931
2010-03-31 $13,015
2009-12-31 $15,836
2009-09-30 $7,490
2009-06-30 $7,863
2009-03-31 $7,121
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $279.310B $81.288B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $447.434B 17.03
Eli Lilly (LLY) United States $287.922B 36.51
AbbVie (ABBV) United States $247.976B 10.54
Novo Nordisk (NVO) Denmark $236.707B 31.22
Merck (MRK) United States $226.779B 11.84
Novartis AG (NVS) Switzerland $192.828B 14.22